Novel Tools for Targeted Therapies in Difficult-to-Treat Rheumatic Diseases

Therapeutic drug monitoring education: The current state

Detection of anti-drug antibodies during monoclonal antibody drug therapy

Quality Assessment of Therapeutic Drug Monitoring Assays of Therapeutic Antibodies Across Europe: An Update

Counteracting tryptophan metabolism alterations as a new therapeutic strategy for rheumatoid arthritis

A specific diagnostic metabolome signature in adult IgA vasculitis

2023 French recommendations for diagnosing and managing prepatellar and olecranon septic bursitis

Comparison of SARS-COV-2 humoral response between rheumatoid arthritis, psoriatic arthritis and spondyloarthritis patients and controls in two unvaccinated cohorts

Therapeutic drug monitoring of monoclonal antibodies in chronic inflammatory diseases: A snapshot of laboratories and applications across Europe

Septic arthritis of the facet joint is also a severe vertebral infection: A multicenter retrospective study of 65 patients

Bispecific antibodies tethering innate receptors induce human tolerant-dendritic cells and regulatory T cells

Response to Biologic Drugs in Patients With Rheumatoid Arthritis and Antidrug Antibodies

Association between radiographic and functional outcome in vertebral osteomyelitis SPONDIMMO, a 6-month prospective multicenter cohort

EULAR points to consider for therapeutic drug monitoring of biopharmaceuticals in inflammatory rheumatic and musculoskeletal diseases

Management and outcome of native joint septic arthritis: a nationwide survey in French rheumatology departments, 2016-2017

Spine immobilization and neurological outcome in vertebral osteomyelitis SPONDIMMO, a prospective multicentric cohort

Large increase of vertebral osteomyelitis in France: a 2010-2019 cross-sectional study

Poor assessment of bone mineral density after a forearm fracture in women aged 50 years or older: Data from a French health insurance database

2020 French recommendations on the management of septic arthritis in an adult native joint

[Rheumatology, the multitude of options]

Practical recommendations for the use of therapeutic drug monitoring of biopharmaceuticals in inflammatory diseases

Current Practices for Therapeutic Drug Monitoring of Biopharmaceuticals in Pediatrics

Biopharmaceuticals: Reference Products and Biosimilars to Treat Inflammatory Diseases

Current Practice for Therapeutic Drug Monitoring of Biopharmaceuticals in Spondyloarthritis

Rationale for Therapeutic Drug Monitoring of Biopharmaceuticals in Inflammatory Diseases

Comparison of the Big Five personality traits in fibromyalgia and other rheumatic diseases

Current Practice for Therapeutic Drug Monitoring of Biopharmaceuticals in Rheumatoid Arthritis

Therapeutic Drug Monitoring of Biopharmaceuticals May Benefit From Pharmacokinetic and Pharmacokinetic-Pharmacodynamic Modeling

Serum biomarkers fail to predict response to adalimumab in axial spondyloarthritis: Results from discovery and validation cohorts

Infliximab Treatment Does Not Lead to Full TNF-α Inhibition: A Target-Mediated Drug Disposition Model

Infliximab Efficacy May Be Linked to Full TNF-α Blockade in Peripheral Compartment-A Double Central-Peripheral Target-Mediated Drug Disposition (TMDD) Model

Exposure-Response Relationship of Certolizumab Pegol and Achievement of Low Disease Activity and Remission in Patients With Rheumatoid Arthritis

Methotrexate effect on immunogenicity and long-term maintenance of adalimumab in axial spondyloarthritis: a multicentric randomised trial

Model-Based Therapeutic Drug Monitoring of Infliximab Using a Single Serum Trough Concentration

Adalimumab concentration-based tapering strategy: as good as the recommended dosage

Brief Report: Relationship Between Serum Infliximab Concentrations and Risk of Infections in Patients Treated for Spondyloarthritis

Immunoglobulin G Receptors (FcγR), in Addition to Target-Antigen and Neonatal Fc Receptor (FcRn), Influence Rituximab Pharmacokinetics

The Influence of Underlying Disease on Rituximab Pharmacokinetics May be Explained by Target-Mediated Drug Disposition

Non-Linear Rituximab Pharmacokinetics and Complex Relationship between Rituximab Concentrations and Anti-Neutrophil Cytoplasmic Antibodies (ANCA) in ANCA-Associated Vasculitis: The RAVE Trial Revisited

Increased high molecular weight adiponectin and lean mass during tocilizumab treatment in patients with rheumatoid arthritis: a 12-month multicentre study

CD4+ count-dependent concentration-effect relationship of rituximab in rheumatoid arthritis

Antigenic burden and serum IgG concentrations influence rituximab pharmacokinetics in rheumatoid arthritis patients

Joint manifestations revealing inborn metabolic diseases in adults: a narrative review

Points to consider for cost-effective use of biological and targeted synthetic DMARDs in inflammatory rheumatic diseases: results from an umbrella review and international Delphi study

Therapeutic drug monitoring of biopharmaceuticals in inflammatory rheumatic and musculoskeletal disease: a systematic literature review informing EULAR points to consider

High prevalence of clinical and biological features of metabolic syndrome in patients with epidural lipomatosis: A single-center, retrospective study

High incidence of vertebral osteoporotic fracture within the first year after liver transplantation

Inclusion-body myositis associated with Sjögren's disease: clinical characteristics and comparison with other Sjögren-associated myositis

A Comparative Study of Fibromyalgia, Rheumatoid Arthritis, Spondyloarthritis, and Sjögren's Syndrome; Impact of the Disease on Quality of Life, Psychological Adjustment, and Use of Coping Strategies

Methotrexate effect on immunogenicity and long-term maintenance of adalimumab in axial spondyloarthritis: a multicentric randomised trial

Points to consider for cost-effective use of biological and targeted synthetic DMARDs in inflammatory rheumatic diseases: results from an umbrella review and international Delphi study

Predictors of response to TNF inhibitors in rheumatoid arthritis: an individual patient data pooled analysis of randomised controlled trials

Machine learning reveals the most important psychological and social variables predicting the differential diagnosis of rheumatic and musculoskeletal diseases

International and multidisciplinary expert recommendations for the use of biologics in systemic lupus erythematosus

Non-Linear Rituximab Pharmacokinetics and Complex Relationship between Rituximab Concentrations and Anti-Neutrophil Cytoplasmic Antibodies (ANCA) in ANCA-Associated Vasculitis: The RAVE Trial Revisited